The beneficial CD4+/Treg and CD8+/Treg ratios, observed in tumor-dLNs and in the tumor after heterologous prime-boost in both tumor models, correspond to clinical data that correlates a higher ratio of these cell types with prolonged survival while associating a high prevalence of Tregs with a poor prognosis in several human cancers [35]. The gene discussed is CD4; the disease is neoplasm.